Guidance cut to single-digit; monsoon and margin collapse sour outlook
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Management guided to low double-digit FY27 growth (FY26 call); now guiding single-digit. Monsoon miss (40% June deficit) is real but severe. Bayer/biologicals underperformed guidance.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Dhanuka delivered a sharp miss: -34.6% YoY PAT collapse and -12.6% revenue decline due to severe monsoon deficit (40% shortfall in June) and herbicide-heavy demand crunch. Management cut FY27 guidance from low double-digit growth to single-digit, citing monsoon impact. Despite acknowledged structural drivers (Nagpur capacity expansion, biostimulants re-entry, Bayer ramp), near-term is weak and capex-heavy (₹100+ Cr FY27-28) with unclear payback. Hold reflects strong long-term optionality but significant near-term headwinds and margin pressure.
₹461.9 Cr
Revenue · −12.6% YoY₹36.3 Cr
Reported PAT · −34.6% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Bayer products will drive FY27 growth; full impact of acquisitions
OVERSTATEDBayer India revenue booked last year; Q1 'very nominal.' International setup ongoing; no Q1 revenue.
Maintain margins through price pass-ons and inventory management
MISSOPM 11.9%, margin compression. Price hikes in June unsustainable; reversed by May-July. Revenue-volume both down 12.6-12.7%.
Biostimulants re-introduction as structural growth driver
OVERSTATEDThree products; two launched by call date, third by August end. Contribution to Q1 nil. Total new product ITI 11.56% (low).
Monsoon challenges are cyclical; long-term drivers intact
Partially40% June rainfall deficit; 12.6% revenue decline; herbicide segment down ~25%. PAT collapsed 34.6% YoY.
Low double-digit FY27 revenue growth expected
MISSAnalyst noted 'steep cut in PPT.' Management now guides single-digit growth. Guidance explicitly downgraded.
Earnings quality
What changed since the last call
FY27 revenue guidance cut sharply
DowngradePrior (FY26 call): 'Low double-digit growth.' Current: 'Small single-digit growth' (mid-call). Monsoon 40% June deficit forced revision.
Bayer products ramp delayed
DowngradePrior guidance emphasized 'full impact of acquired Bayer products.' Q1 actual: India revenue 'very nominal', zero in international. Ramp expected Q2+ only.
Biostimulants re-entry minimal impact Q1
DowngradePrior highlighted re-introduction as driver. Q1 actual: only two of three products launched; new product contribution 11.56% (low). Full contribution expected Q2 onward.
Dahej plant remains unprofitable
NeutralQ1 EBITDA near breakeven (₹-1 Cr). Full-year guidance: ₹-4 to -5 Cr EBITDA. Plant not yet accretive to profit; remains capex-heavy cash drag.
Cost inflation not fully passed
DowngradeManagement claimed 'price pass-ons' would maintain margins. June hikes unsustainable; reversed by May-July. Margin compression to 11.9% OPM.
The Q&A
Analysts pressed hard on guidance cuts, Nagpur capex economics (₹200 Cr for 23k MT formulation plant vs. peer ₹60-70 Cr), and delayed Bayer ramp. Management defended capex as 'automation, global-standard safety' but was vague on asset-turn payback. CFO pushed back on capex justification; MD deflected ('How do you arrive at it is high?'). No Q&A hostility, but clear skepticism on forward assumptions.
Bayer revenue contribution — Rushabh Shah, BugleRock PMS
DodgedManagement declined to share: 'As of now, we are not sharing the number...will address separately.'
Guidance cut rationale — Darshita Shah, DSP Asset Managers
AnsweredMonsoon movement and impact forced revised view; 'absolutely appropriate to project clear picture to investors.' Still hopeful Q2/Q3 growth.
Nagpur CAPEX justification — Darshita Shah, DSP Asset Managers
PartialPlant designed for significant automation, global safety standards, labor efficiency. No specific ROI timeline given ('not right time to comment on asset turns').
Dahej plant performance — Darshita Shah, DSP Asset Managers
AnsweredRevenue ₹26 Cr (vs ₹16 Cr prior), EBITDA <₹1 Cr (vs -₹3 Cr prior). Full-year guidance ₹65 Cr revenue; EBITDA loss ₹4-5 Cr.
Bayer product revenue timing — Riju Dalui, Antique Stock Broking
AnsweredIndia business started last year; Q1 'very nominal figure.' Major turnover (grapes/Iprovalicarb) in September Q2.
FY27 growth rate clarity — Archit Joshi, Nuvama IE
AnsweredYes, 'small single-digit growth' for FY27. Biologicals offset crop protection decline.
Biostimulant re-entry progress — Rohit Nagraj, 360 ONE Capital
AnsweredTwo already introduced; third by August end. Two more nutrition biologicals in FY27. All regulatory approvals received.
Nagpur plant timeline and benefits — Rohit Nagraj, 360 ONE Capital
AnsweredQ4 FY28 commissioning. CGST benefits from Maharashtra govt received.
Capex plan across FY27-29 — Himanshu Binani, Anand Rathi
PartialFY27-28: ~₹100 Cr Nagpur CAPEX. Dahej details TBD. No benefit quantification given.
Biologicals market-share impact — Saurabh Jain, HSBC
PartialRegulation design favors organized. Smaller/unorganized will have 'relatively lesser room to operate.' 'I hope so' we capture share.
Dahej EBITDA breakeven — Saurabh Jain, HSBC
AnsweredNo. 'Breakeven appears to be difficult...around negative ₹4-5 Cr.' They are 'trying hard, but I think it is difficult.'
Volume vs. price breakdown — Riju Dalui, Antique Stock Broking
AnsweredAlmost equal. Value down 12.56%, volume down 12.7%. Price hike June unsustainable; reversed by May-July. No net price growth.
Farmer stress and crop protection spending — Umang Shah, Banyan Tree Advisors
PartialDepends on irrigation. Irrigated farms (60%) will spend more; rain-fed will opt for low-cost options. Vegetable prices up, supporting horticulture demand.
Guidance
FY27 small single-digit growth (cut from low double-digit)
MediumMonsoon-dependent. Based on June 40% rain deficit improving to 15% by July end. Growth contingent on Q2-Q3 recovery and biostimulant ramp.
OPM to remain under pressure; Dahej EBITDA loss ₹4-5 Cr in FY27
MediumCost inflation not fully passed through (price hikes June unsustainable). Margin compression evident in Q1 (11.9% OPM).
Nagpur plant ~₹100 Cr in FY27-28; total ₹200 Cr by April 2028
HighLand acquired, project in planning phase. Automated formulation facility with CGST benefits. Dahej capex details TBD.
Risks the call surfaced
Monsoon & sowing risk
HighJune rainfall 40% below normal; delayed sowing in Rajasthan, Gujarat, MP, Maharashtra. Herbicides (42% of mix) down ~25%. Risk: Further monsoon deficit in July-Sept would deepen downturn.
Margin compression
HighRaw material and logistics costs elevated. June price hikes (offset geopolitical tensions in West Asia) unsustainable; reversed by May-July. OPM 11.9% compressed. PAT down 34.6% despite cost controls (expenses flat). Weak demand limited pass-through.
Dahej plant underutilization
MediumDahej chemical synthesis facility Q1 revenue ₹26 Cr, EBITDA near zero (₹-1 Cr). Full-year guidance: ₹-4 to -5 Cr EBITDA loss. Plant acquired via Bayer deal; not yet profitable. Risk: Multi-year drag on group profitability.
Bayer products delayed ramp
MediumBayer India business generated minimal Q1 revenue ('very nominal'). International setup (Brazil, Europe distributors) ongoing; no revenue booked. Major ramp (grapes/Iprovalicarb) expected Q2+ (September). Risk: Timing slip or market adoption slower than expected.
Biostimulants re-entry unproven
MediumBiostimulants/biologicals were banned. Two of three products just relaunched by call date; third by Aug end. New product ITI only 11.56% of Q1 revenue. Analyst estimated ₹130 Cr opportunity, but MD frames as 'fallback option' and 'reworking category.' Risk: Market adoption slow or margins compressed vs. expectations.
Guidance downgrade and credibility
MediumFY26 call promised 'low double-digit FY27 revenue growth.' Q1 delivered -12.6% decline. Guidance cut to 'single-digit growth' (disclosed in Q&A, not proactively). Multiple analysts pressed on cut severity. Risk: Repeat miss could further erode credibility.
GST notice contingency
LowGST notice received on certain molecules (biostimulant classification). CFO confident will win (categorized as fertilizer, 5% rate vs. higher rate). Unresolved; resolution timeline TBD.
Management
Score 6/10. Mixed. Transparent on numbers (matched delivered results exactly), monsoon impact, and margin pressure. Evasive on Bayer/biologicals revenue guidance ('not sharing'; 'exact figure difficult'). Defensive on capex justification (Darshita Shah questioned ₹200 Cr; MD deflected). Weak Q1 (miss vs. guidance), but acknowledged monsoon headwinds. Dahej plant still in red; Bayer/biologicals delayed ramp. Track record: promised low double-digit FY27 growth, delivered -12.6% revenue, -34.6% PAT, guidance cut. Cost controls are credible; capex expansion on track (Nagpur land acquired).
1 · Q2 FY27 (Jul-Sep)
Bayer India (grapes) turnover ramp; biostimulants #3 product launch by August; monsoon recovery tracking
2 · Q4 FY28
Nagpur formulation plant (23k MT/annum) operational; automation-driven capacity +23k MT
3 · FY27 YE
GST notice resolution (pending; CFO confident of 5% refund); two more biostimulant products launched
Hold reflects strong long-term optionality but significant near-term headwinds and margin pressure.
Monsoon Miss, Guidance Cut, and the Structural Driver Delay
Dhanuka promised low double-digit FY27 revenue growth on the prior-year call. Q1 delivered −12.6% revenue and −34.6% profit, forcing a guidance cut to single-digit growth. The monsoon is real, but so is the delay in every strategic driver the company had leaned on.
Low double-digit growth
Revenue, from FY26 call
−12.6% YoY
Revenue; PAT −34.6%
Single-digit growth
Cut on this call mid-quarter
The revenue line is a clean miss: Dhanuka guided low double-digit growth for FY27 in the prior call; Q1 delivered a 12.6% decline. Profit fell harder still—down 34.6% year-over-year to ₹36.3 Cr. The company revised its full-year guidance downward in the presentation, citing a 40% June monsoon deficit and weak sowing. But the miss isn't monsoon alone. Every structural driver management had positioned for FY27 ramp—Bayer products, biostimulant re-entry, margin maintenance—either underperformed or delayed. The combination has cost credibility and reset expectations.
What Management Promised vs. What Q1 Delivered
Low double-digit FY27 revenue growth
ContradictedQ1: −12.6% YoY. Guidance cut to single-digit mid-quarter.
Bayer acquisition will drive full-impact FY27 growth
OverstatedQ1 Bayer India revenue 'very nominal.' International setup ongoing; zero revenue. Ramp expected Q2+ (September grapes/Iprovalicarb).
Maintain margins via price pass-ons and inventory management
ContradictedOPM 11.9% (compressed). June price hikes unsustainable; reversed by May-July. Volume and value both down 12.6–12.7% (pure demand loss).
Biostimulants re-introduction will be a structural driver
OverstatedOnly 2 of 3 products launched by call date; third by August end. New product revenue 11.56% of Q1 (low). Contribution nil to Q1 top-line.
Monsoon challenges are cyclical; long-term drivers intact
Partially trueMonsoon severe (40% June deficit confirmed). But Bayer/biologicals delays + Dahej ₹−4 to −5 Cr EBITDA guidance show execution gaps beyond weather.
The monsoon hit is undeniable: June rainfall was 40% below normal in key agro regions (Rajasthan, Gujarat, Madhya Pradesh, Maharashtra), delaying sowing and crushing demand for herbicides—which account for 42% of Dhanuka's product mix and fell approximately 25% year-over-year. But within that macro shock, the company's own momentum stalled. Bayer products, touted as a near-term growth lever, contributed nearly nothing to Q1 revenues. Biostimulants, relaunched after regulatory clearance, remain a token part of the quarter. Dahej, the chemical synthesis facility acquired via the Bayer deal, posted ₹26 Cr revenue but an EBITDA loss of ~₹1 Cr in Q1, and management now guides ₹−4 to −5 Cr full-year EBITDA loss—a multi-quarter profit drag. None of these are monsoon excuses. They are execution delays.
What Changed on This Call
The Bull-Bear Ledger
Pan-India scale: 10M+ farmers, 6,500 distributors, 80,000 retailers; supply chain resilience
Structural drivers (Nagpur capacity expansion, biostimulants, Bayer international) are real multi-year plays
Innovation-focused: 13.89% Innovation Turnover Index; new products like MYCORe SUPER gaining traction
Debt-free balance sheet; cash generation 'continue to remain strong' per MD
Q1 miss −12.6% revenue, −34.6% PAT with guidance cut erodes credibility for near-term
Dahej plant ₹−4 to −5 Cr EBITDA loss guidance; capex unaccretive for multi-year horizon
Bayer/biologicals upside now backloaded to Q2+ (timing risk remains)
Nagpur capex ₹200 Cr (vs. peer ₹60–70 Cr for similar facilities); ROI timeline deferred to 'late Q4'
Herbicide segment (42% of mix) is cyclical; 25% decline in sowing-weak quarter shows volatility
Monsoon dependency: 60% of Indian farms rain-fed; 1% rainfall shortfall impacts sowing. June 40% deficit a severe shock.
Risks, Ranked by Holder Impact
Guidance credibility erosion
HighPrior FY27 call: low double-digit growth. Q1 delivery: −12.6%, forcing single-digit cut. Analysts pressed ('steep cut'). If Q2 disappoints again, institutional support erodes further (FII already trimmed 0.73pp this fiscal year).
Monsoon volatility and herbicide cyclicality
HighHerbicides 42% of mix, down ~25% YoY in June-deficit quarter. Profit fell 34.6%. Small rainfall swings (40% deficit in June, forecast 15% by July end) drive outsized P&L swings. No pricing power in weak demand.
Margin compression despite cost control
HighOPM 11.9%, compressed. Cost inflation ongoing; pre-committed for expected season. Price hikes unsustainable (reversed by July). Weak demand leaves no room for pass-through. Margin trajectory uncertain.
Dahej plant unprofitable multi-year drag
HighFY27 guided ₹−4 to −5 Cr EBITDA loss. Q1 EBITDA ~₹−1 Cr despite ₹26 Cr revenue. Plant remains capex sink until Bayer ramp scales it. Delays profit accretion.
Bayer/biologicals upside deferred and unquantified
MediumManagement refused to quantify Bayer FY27 contribution ('not sharing the number'). Bayer India Q1 'very nominal'; international zero. Ramp expected Q2+, but timing risk high. Biologicals framed as 'fallback option'—low conviction language.
Nagpur capex ROI timeline opaque
Medium₹200 Cr capex for 23,000 MT/annum formulation facility (peers: ₹60–70 Cr). Analyst pressed on economics; MD deflected ('How do you arrive at it is high?'). Asset-turn payback deferred to 'late Q4 when project details finalized.' Capex-heavy near-term with unclear long-term return.
GST notice outcome pending
LowCFO confident ('no doubt about it') on winning biostimulant classification as fertilizer (5% rate). But legal case ongoing; resolution timeline unspecified. If lost, affects bio-product profitability.
How the Street Is Positioned
The market registered its verdict quickly. The stock closed day 1 post-result at −1.2% (vs. pre-result ₹1,023.3), with heavy delivery (60.3%), signaling institutional selling. The pop never filled in; by day 3, the stock had recovered only +0.32%, settling at ₹1,026.6 on 2026-08-06—still near the opening low. The price action confirms the miss: no +2% pop, no sustained relief, just capitulation and narrow consolidation. The technical backdrop is weak. The stock is trading below its 50-day average (₹1,055.35) and 200-day average (₹1,112.87), though above the 20-day (₹1,020.6). It is down 30.16% from its all-time high of ₹1,470, off the 52-week low of ₹890 by only 15.35%, sitting in the lower half of its annual range. RSI at 53.4 is neutral—not oversold, but not offering any technical support. Institutional flows confirm the growth disappointment. FII ownership has declined from 2.66% (Q1 FY26) to 1.93% (Q4 FY26), a drop of 73 basis points, consistent with a growth miss and margin pressure in an otherwise stable business. DII has picked up 1.80pp in that same period, but promoter ownership remains flat at ~69.7%, offering no insider support signal. The ownership mix suggests institutional indifference—foreigners are leaving, domestic money is moving in (possibly on value), promoter is not buying.
The Debate
What to Watch Next
1 · Q2 Bayer turnover and monsoon recovery tracking
Bayer India is expected to ramp in Q2 (September grapes/Iprovalicarb). Quantify contribution, even if 'not sharing the full number.' Monsoon deficit forecast 15% by July end—confirm sowing normalizes in Q2+ and acreage recovers. If both happen and Bayer revenue is visible (even ₹5–10 Cr), bulls get credibility back.
2 · Dahej EBITDA trajectory and profitability path
Q1 Dahej: ₹−1 Cr EBITDA on ₹26 Cr revenue. Full-year guidance ₹−4 to −5 Cr loss. If Q2 shows stabilization or a path to breakeven by Q3/Q4, it signals Bayer utilization is ramping. If Q2 EBITDA remains negative (−₹1 to −2 Cr), the plant is a longer-term drag than expected.
3 · Nagpur capex progress and ROI quantification
₹200 Cr capex for 23,000 MT/annum facility (April 2028 commissioning). Management deferred ROI details to late Q4. At Q2 or Q3 update, demand clarity on asset turnover, payback period, and automation efficiency gains. Investors will re-rate based on capex quality, not just land acquisition.
Dhanuka is a stable, large-cap agrochemical player with real long-term drivers and a debt-free balance sheet. But this quarter broke the near-term growth narrative and left room for structural margin pressure. The monsoon is a real shock—40% June deficit is severe—but the company's own execution gaps (Bayer delay, Dahej unprofitable, biologicals nil contribution) are independent of weather and signal the FY27 reacceleration won't be as sharp as prior guidance promised.
The Hold rating reflects that tension: optionality in long-term drivers (Bayer international, Nagpur plant, organized-sector biologicals share) offset by near-term weakness, capex overhang, and credibility erosion. Q2 will settle whether this is a cyclical bounce or a lower-growth, lower-margin normalize. Track organic revenue growth (not just guidance) and Bayer/Dahej contribution carefully. The stock at ₹1,026 reflects that ambiguity—not cheap enough for deep-value entry, not confident enough for growth positioning. Wait for Q2 visibility before scaling into a longer-term position.
Dhanuka Q1 PAT sinks 35% YoY to ₹36 Cr as revenue slips 13%, margins compress hard
PAT -34.59% YoY · revenue -12.56% · margins compressing · miss vs street
₹461.93 Cr
-12.56% YoY
₹36.3 Cr
-34.59% YoY
7.71%
-2.6pp YoY
₹8.06
Dhanuka Agritech opened FY27 with a weak, demand-led print: standalone revenue fell 12.6% YoY to ₹461.9 Cr and net profit dropped 34.6% YoY to ₹36.3 Cr (EPS ₹8.06 vs ₹12.31). This badly misses street and management's own set-up — Uniresearch had pencilled in ₹564 Cr revenue (+6.9%) and ₹64 Cr PAT (+14.3%), and on the Q1 FY26 concall management had guided to low-double-digit FY27 revenue growth on the full-year impact of acquired Bayer products and re-introduced biostimulants. Q1 delivered the opposite of that guidance on the topline, with the agri-input cyclicality management always flags (monsoon, pest, crop patterns) working against it this quarter.
Q1 FY-2027 vs prior quarters
The damage is operating deleverage, not a one-off: with no exceptional items on either side, the profit fall is genuine. Net margin compressed to 7.9% from 10.5% a year ago, and EBIT-level margin thinned as expenses (₹422.2 Cr) fell far less than revenue — employee cost (₹46.5 Cr) and other expenses (₹60.9 Cr) were essentially flat YoY against a shrunken topline, while other income of ₹8.9 Cr and lower finance cost cushioned only marginally. The sequential optics are worse still (PAT ₹36.3 Cr vs ₹97.8 Cr in Q4) but that is a seasonality artifact — Q4 is Dhanuka's strong rabi quarter and is not the right comparison; YoY is the clean read here.
The stock went into the print at ₹981.6, down 10.1% over the past month of trading.
What the summary numbers don't show
Standalone revenue ₹461.9 Cr, down 12.6% YoY (₹528.3 Cr) and 4.4% QoQ (₹483.3 Cr)
Management provided a positive outlook for FY27, expecting low double-digit revenue growth, driven by the full impact of acquired Bayer products and the re-introduction of biostimulants. While EBITDA margins are expected to moderate slightly due to the absence of a significant GST refund in FY26, the company anticipate
— This quarter: missed
The board paired the soft result with two capital moves signalling continued confidence in the runway: approval of up to ₹200 Cr for a new 23,000 MT/annum pesticide plant at Nagpur (operational by Mar/Apr 2028, funded by internal accruals/debt) to shorten lead times into South, East and Central India, and a ₹15 Cr loan to the employee trust for the SAR 2026 plan — on top of the ₹70 Cr buyback executed during the quarter. Q2 (kharif) will test whether the guided low-double-digit growth and Bayer/biostimulant contribution actually materialise, or whether the FY27 outlook needs to be reset lower.
W1
Q2 (kharif) topline recovery — must show growth to salvage the guided low-double-digit FY27 revenue target after a -12.6% Q1
W2
Contribution ramp from acquired Bayer products and re-introduced biostimulants, the pillars of the FY27 growth thesis
W3
Net margin trajectory off the 7.9% Q1 base — whether operating leverage returns as volumes normalise
Standalone only; single segment (Agro Chemicals). Source in ₹ lacs, converted to Cr. No exceptional items either period. ₹70 Cr buyback of 5,00,000 shares @ ₹1,400 extinguished 20-Jun-26, reducing share capital.